PGx testing for warfarin metabolism has received the most attention thus far.
Recent studies have revealed that about half of the variations seen in patients taking the anticoagulant warfarin are due to PGx factors. The consequences of incorrect warfarin dosing are obviously serious, with inadequate doses predisposing patients to thrombosis and higher doses placing them at risk for hemorrhage.
Labeling for Coumadin (warfarin sold by Bristol-Myers Squibb) recommends that physicians incorporate PGx information into warfarin-dosing regimens for patients. Manufacturers of generic warfarin products are also adding similar labeling.